\-\ Texto\\:\\ \ \(0\)\
\-\ total\\ protein\\ in\\ 24\\ hours\\ 4598\\ \\(42\\-225mg\\/24h\\)\ \(0\)\
\-\ ldh\\ 772\\ \\(313\\-618\\)\ \(0\)\
\-\ alk\\ phos\\ 298\\ \\(38\\-126\\)\ \(0\)\
\-\ serum\\ sodium\\ 131\\ \\(137\\-148\\)\ \(0\)\
\-\ esr\\ 82\ \(0\)\
\-\ pt\\ was\\ given\\ dilantin\\ and\\ magnesium\\ until\\ after\\ delivery\\ of\\ child\\.\\ follow\\ up\\ mri\\ was\\ performed\\ 2\\ months\\ later\\.\ \(0\)\
\-\ on\\ the\\ first\\ set\\ of\\ images\\ there\\ is\\ subcortical\\ white\\ matter\\ t2\\ and\\ flair\\ hyperintensity\\ in\\ the\\ occipital\\ and\\ parietal\\ lobes\\ in\\ the\\ distribution\\ of\\ the\\ posterior\\ circulation\\.\\ there\\ is\\ also\\ abnormal\\ fluid\\ signal\\ in\\ the\\ anterior\\ cerebral\\/middle\\ cerebral\\ artery\\ watershed\\ area\\ without\\ abnormal\\ gray\\ matter\\ signal\\.\\ there\\ is\\ mild\\ increased\\ signal\\ on\\ diffusion\\ weighted\\ imaging\\ in\\ the\\ areas\\ of\\ high\\ t2\\ signal\\ intensity\\,\\ but\\ no\\ associated\\ adc\\ abnormality\\ to\\ suggest\\ infarct\\.\ \(0\)\
\-\ posterior\\ reversible\\ leukoencephalopathy\\ syndrome\\ \\(pres\\)\ \(0\)\
\-\ edema\\ from\\ posterior\\ reversible\\ leukoencephalopathy\ \(0\)\
\-\ ischemia\\ related\\ changes\\ secondary\\ to\\ seizure\ \(0\)\
\-\ demyelinating\\ process\ \(0\)\
\-\ posterior\\ circulation\\ ischemia\\ or\\ infarction\ \(0\)\
\-\ 20\\ y\\.o\\.\\ pregnant\\ woman\\ \\(g1p0\\)\\ with\\ 36wga\\ intra\\ uterine\\ pregnancy\\ and\\ eclampsia\\ with\\ severe\\ headaches\\,\\ seizure\\ activity\\ and\\ visual\\ disturbance\\.\ \(0\)\
\-\ delivery\\ of\\ child\\ caused\\ remission\\ of\\ clinical\\ symptoms\\ and\\ the\\ follow\\ up\\ mri\\ had\\ interval\\ resolution\\ of\\ all\\ abnormalities\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ leukoencephalopathy\\:\\ 0\\.06077073503661881\ \(0\)\
\-\ reversible\\:\\ 0\\.05871257405751982\ \(0\)\
\-\ circulation\\:\\ 0\\.053380518064843833\ \(0\)\
\-\ signal\\:\\ 0\\.046216909338928795\ \(0\)\
\-\ 4598\\:\\ 0\\.04520778678957178\ \(0\)\
\-\ 42\\-225mg\\/24h\\:\\ 0\\.04520778678957178\ \(0\)\
\-\ 772\\:\\ 0\\.04520778678957178\ \(0\)\
\-\ 298\\:\\ 0\\.04520778678957178\ \(0\)\
\-\ 137\\-148\\:\\ 0\\.04520778678957178\ \(0\)\
\-\ cerebral\\/middle\\:\\ 0\\.04520778678957178\ \(0\)\
\-\ 36wga\\:\\ 0\\.04520778678957178\ \(0\)\
\-\ delivery\\:\\ 0\\.04497129871921214\ \(0\)\
\-\ ischemia\\:\\ 0\\.04073160346161956\ \(0\)\
\-\ posterior\\:\\ 0\\.04040284202466561\ \(0\)\
\-\ 313\\-618\\:\\ 0\\.03957387761691481\ \(0\)\
\-\ seizure\\:\\ 0\\.038754521246696094\ \(0\)\
\-\ child\\:\\ 0\\.03836250880751458\ \(0\)\
\-\ eclampsia\\:\\ 0\\.03809858493767491\ \(0\)\
\-\ magnesium\\:\\ 0\\.03695425903349948\ \(0\)\
\-\ watershed\\:\\ 0\\.03695425903349948\ \(0\)\
\-\ dilantin\\:\\ 0\\.034543984011726474\ \(0\)\
\-\ matter\\:\\ 0\\.034507486875905616\ \(0\)\
\-\ 38\\-126\\:\\ 0\\.033399658107551036\ \(0\)\
\-\ 131\\:\\ 0\\.03205420034105108\ \(0\)\
\-\ g1p0\\:\\ 0\\.03167415945821148\ \(0\)\
\-\ pres\\:\\ 0\\.0313203498608425\ \(0\)\
\-\ disturbance\\:\\ 0\\.0313203498608425\ \(0\)\
\-\ remission\\:\\ 0\\.030989383085778033\ \(0\)\
\-\ set\\:\\ 0\\.02935628702875991\ \(0\)\
\-\ sodium\\:\\ 0\\.029128329271986404\ \(0\)\
\-\ intra\\:\\ 0\\.02830605927160087\ \(0\)\
\-\ follow\\:\\ 0\\.027848199712271118\ \(0\)\
\-\ ldh\\:\\ 0\\.027434782159829595\ \(0\)\
\-\ 82\\:\\ 0\\.02712388666333506\ \(0\)\
\-\ demyelinating\\:\\ 0\\.02712388666333506\ \(0\)\
\-\ subcortical\\:\\ 0\\.026690259032421917\ \(0\)\
\-\ adc\\:\\ 0\\.026163827473139438\ \(0\)\
\-\ pregnant\\:\\ 0\\.025801686102811472\ \(0\)\
\-\ alk\\:\\ 0\\.025573728346037966\ \(0\)\
\-\ phos\\:\\ 0\\.025573728346037966\ \(0\)\
\-\ abnormal\\:\\ 0\\.024995817849383706\ \(0\)\
\-\ t2\\:\\ 0\\.024806038653849765\ \(0\)\
\-\ hyperintensity\\:\\ 0\\.02412638235791378\ \(0\)\
\-\ up\\:\\ 0\\.023567663087735623\ \(0\)\
\-\ protein\\:\\ 0\\.02248564935960607\ \(0\)\
\-\ uterine\\:\\ 0\\.02248564935960607\ \(0\)\
\-\ \\(\\:\\ 0\\.02222651465365725\ \(0\)\
\-\ esr\\:\\ 0\\.022189138739663376\ \(0\)\
\-\ \\)\\:\\ 0\\.02195500591117862\ \(0\)\
\-\ interval\\:\\ 0\\.021489977490678085\ \(0\)\
\-\ gray\\:\\ 0\\.021439945824291602\ \(0\)\
\-\ serum\\:\\ 0\\.021149592521730026\ \(0\)\
\-\ occipital\\:\\ 0\\.02044720352135486\ \(0\)\
\-\ mri\\:\\ 0\\.020136162614508922\ \(0\)\
\-\ flair\\:\\ 0\\.02009065961033634\ \(0\)\
\-\ visual\\:\\ 0\\.01986603077619074\ \(0\)\
\-\ distribution\\:\\ 0\\.01972156474046409\ \(0\)\
\-\ diffusion\\:\\ 0\\.019615824806091087\ \(0\)\
\-\ there\\:\\ 0\\.01956485471484598\ \(0\)\
\-\ infarct\\:\\ 0\\.01944429693907806\ \(0\)\
\-\ lobes\\:\\ 0\\.019311089316497238\ \(0\)\
\-\ until\\:\\ 0\\.019245760979177084\ \(0\)\
\-\ weighted\\:\\ 0\\.019054625621242563\ \(0\)\
\-\ resolution\\:\\ 0\\.018900613892530383\ \(0\)\
\-\ total\\:\\ 0\\.01887035890726275\ \(0\)\
\-\ pregnancy\\:\\ 0\\.018840281371609424\ \(0\)\
\-\ parietal\\:\\ 0\\.018721704872015302\ \(0\)\
\-\ suggest\\:\\ 0\\.018663429186629072\ \(0\)\
\-\ caused\\:\\ 0\\.01838158875442006\ \(0\)\
\-\ related\\:\\ 0\\.018088468683445966\ \(0\)\
\-\ infarction\\:\\ 0\\.01791029971706713\ \(0\)\
\-\ hours\\:\\ 0\\.0172317810697887\ \(0\)\
\-\ 24\\:\\ 0\\.017038240926286922\ \(0\)\
\-\ process\\:\\ 0\\.016872130691460072\ \(0\)\
\-\ headaches\\:\\ 0\\.016750986354211683\ \(0\)\
\-\ activity\\:\\ 0\\.016441264762982247\ \(0\)\
\-\ pt\\:\\ 0\\.01629314745965514\ \(0\)\
\-\ abnormality\\:\\ 0\\.016166963814515652\ \(0\)\
\-\ abnormalities\\:\\ 0\\.016096228829221623\ \(0\)\
\-\ intensity\\:\\ 0\\.015839336801945134\ \(0\)\
\-\ later\\:\\ 0\\.01582265969739961\ \(0\)\
\-\ 20\\:\\ 0\\.0157564883905488\ \(0\)\
\-\ cerebral\\:\\ 0\\.01518177693212344\ \(0\)\
\-\ given\\:\\ 0\\.015022637910340218\ \(0\)\
\-\ areas\\:\\ 0\\.014745370108954188\ \(0\)\
\-\ first\\:\\ 0\\.014705043255312062\ \(0\)\
\-\ white\\:\\ 0\\.014533867757497527\ \(0\)\
\-\ area\\:\\ 0\\.013855570482739832\ \(0\)\
\-\ severe\\:\\ 0\\.013483640000338483\ \(0\)\
\-\ clinical\\:\\ 0\\.013483640000338483\ \(0\)\
\-\ artery\\:\\ 0\\.013048871754401021\ \(0\)\
\-\ y\\.o\\:\\ 0\\.01264809965429077\ \(0\)\
\-\ changes\\:\\ 0\\.012559220390949028\ \(0\)\
\-\ syndrome\\:\\ 0\\.012532854239664827\ \(0\)\
\-\ fluid\\:\\ 0\\.01245455951078899\ \(0\)\
\-\ edema\\:\\ 0\\.012394479432980979\ \(0\)\
\-\ all\\:\\ 0\\.012394479432980979\ \(0\)\
\-\ secondary\\:\\ 0\\.012251435725686191\ \(0\)\
\-\ performed\\:\\ 0\\.012218350416550354\ \(0\)\
\-\ high\\:\\ 0\\.01199254390295803\ \(0\)\
\-\ months\\:\\ 0\\.011968929716359319\ \(0\)\
\-\ mild\\:\\ 0\\.011539761302210958\ \(0\)\
\-\ anterior\\:\\ 0\\.011286117044937115\ \(0\)\
\-\ symptoms\\:\\ 0\\.010921320394349432\ \(0\)\
\-\ in\\:\\ 0\\.01080505718308346\ \(0\)\
\-\ increased\\:\\ 0\\.010720434778459773\ \(0\)\
\-\ associated\\:\\ 0\\.010340833650808727\ \(0\)\
\-\ without\\:\\ 0\\.010318016237734155\ \(0\)\
\-\ imaging\\:\\ 0\\.010267045253618476\ \(0\)\
\-\ was\\:\\ 0\\.010136179715012173\ \(0\)\
\-\ woman\\:\\ 0\\.010122579217891827\ \(0\)\
\-\ had\\:\\ 0\\.009455640098670299\ \(0\)\
\-\ 2\\:\\ 0\\.009436433315438699\ \(0\)\
\-\ but\\:\\ 0\\.009346170774530963\ \(0\)\
\-\ after\\:\\ 0\\.009066672833893346\ \(0\)\
\-\ is\\:\\ 0\\.00865062735976501\ \(0\)\
\-\ also\\:\\ 0\\.00863907483933411\ \(0\)\
\-\ images\\:\\ 0\\.008406481497176174\ \(0\)\
\-\ on\\:\\ 0\\.00742452320374798\ \(0\)\
\-\ from\\:\\ 0\\.00649454211873955\ \(0\)\
\-\ and\\:\\ 0\\.0055387386379144145\ \(0\)\
\-\ or\\:\\ 0\\.005136014097249782\ \(0\)\
\-\ the\\:\\ 0\\.0049627948355147715\ \(0\)\
\-\ no\\:\\ 0\\.004412534106173344\ \(0\)\
\-\ to\\:\\ 0\\.004380185727620372\ \(0\)\
\-\ of\\:\\ 0\\.00418218772095343\ \(0\)\
\-\ \\,\\:\\ 0\\.002776513492484999\ \(0\)\
\-\ \\.\\:\\ 0\\.0014563912245065139\ \(0\)\
\-\ with\\:\\ 0\\.0012000428316911768\ \(0\)\
